<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00170911</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE581A1201</org_study_id>
    <nct_id>NCT00170911</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia/Osteoporosis.</brief_title>
  <official_title>Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia/Osteoporosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      AAE581 is a specific inhibitor of the cysteine protease cathepsin K. This trial is designed
      to provide detailed information about the effects( efficacy and safety) of AAE581 on Bone
      Mineral Density.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of lumbar spine(L1-L4)BMD at 12 months</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of 12 month treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of BMD of lumbar spine(L1-L4,L2-L4)„ÄÅtotal hip, femoral neck, forearm and total body at 3, 6, 9 and 12 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Bone markers(Serum CTX,P1NP, OC, BSAP and urinary NTX, DPyr at 1,3,6,9 and 12 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of AAE581 and AEE325 at 1,3,6,9 and 12 months</measure>
  </secondary_outcome>
  <enrollment>160</enrollment>
  <condition>Osteoporosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AAE581</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Low spine Bone Mineral Density

          -  0 to 1 prevalent fracture in non lumber spine

        Exclusion Criteria:

          -  History or presence of any bone disease other than osteopenia /osteoporosis

          -  Previous treatment with other anti-osteoporosis agent(Wash out required)

          -  Evidence of vitamin D deficiency

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Chair</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>November 1, 2011</last_update_submitted>
  <last_update_submitted_qc>November 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>Postmenopausal women</keyword>
  <keyword>Cathepsin K inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

